Artia Global Partners LP Has $14.02 Million Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Artia Global Partners LP grew its stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 22.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 767,098 shares of the company’s stock after acquiring an additional 138,731 shares during the period. Eyepoint Pharmaceuticals accounts for 1.9% of Artia Global Partners LP’s holdings, making the stock its 13th largest position. Artia Global Partners LP owned about 0.93% of Eyepoint Pharmaceuticals worth $14,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of EYPT. Paradigm Biocapital Advisors LP acquired a new stake in Eyepoint Pharmaceuticals during the third quarter worth approximately $28,556,000. Orbimed Advisors LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the third quarter valued at approximately $25,575,000. Federated Hermes Inc. raised its position in shares of Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after buying an additional 1,601,101 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Eyepoint Pharmaceuticals by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock valued at $88,100,000 after buying an additional 1,027,623 shares in the last quarter. Finally, Spruce Street Capital LP acquired a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter valued at approximately $17,933,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on EYPT shares. Citigroup lifted their price target on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Royal Bank Of Canada dropped their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. HC Wainwright lifted their price objective on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Chardan Capital lifted their price objective on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $31.80.

Insider Buying and Selling at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.13% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $13.15 on Thursday. The company’s 50 day simple moving average is $13.28 and its 200 day simple moving average is $14.66. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.76 and a beta of 1.72. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $7.94 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. As a group, analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.09 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.